Daiichi Company Profile

✉ Email this page to a colleague

DAIICHI has four approved drugs.

There are twenty-five US patents protecting DAIICHI drugs.

There are three hundred and thirty-four patent family members on DAIICHI drugs in forty-seven countries and thirty-nine supplementary protection certificates in eighteen countries.

International Patents:	334
US Patents:	25
Tradenames:	4
Ingredients:	4
NDAs:	4
Patent Litigation for Daiichi:	See patent lawsuits for Daiichi
PTAB Cases with Daiichi as patent owner:	See PTAB cases with Daiichi as patent owner

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-002	Oct 14, 2022		RX	Yes	Yes	9,802,932	⤷ Start Trial		Y		⤷ Start Trial
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		DISCN	Yes	No	9,358,235	⤷ Start Trial				⤷ Start Trial
Daiichi Sankyo Inc	VANFLYTA	quizartinib dihydrochloride	TABLET;ORAL	216993-001	Jul 20, 2023		RX	Yes	No	8,865,710	⤷ Start Trial	Y			⤷ Start Trial
Daiichi Sankyo Inc	SAVAYSA	edoxaban tosylate	TABLET;ORAL	206316-003	Jan 8, 2015		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-002	Oct 14, 2022		RX	Yes	Yes	10,435,404	⤷ Start Trial	Y			⤷ Start Trial
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-002	Oct 14, 2022		RX	Yes	Yes	8,404,700	⤷ Start Trial		Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Daiichi	FLOXIN OTIC	ofloxacin	SOLUTION/DROPS;OTIC	020799-001	Dec 16, 1997	5,401,741	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	15 mg, 30 mg and 60 mg	➤ Subscribe	2019-01-28

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2008063888	⤷ Start Trial
Russian Federation	2441011	⤷ Start Trial
South Korea	20180015142	⤷ Start Trial
China	107548394	⤷ Start Trial
Japan	2012521435	⤷ Start Trial
Taiwan	200920360	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1405852	122015000077	Germany	⤷ Start Trial	PRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
1405852	C01405852/01	Switzerland	⤷ Start Trial	PRODUCT NAME: EDOXABAN; REGISTRATION NO/DATE: SWISSMEDIC 65149 31.03.2015
2429524	2490010-2	Sweden	⤷ Start Trial	PRODUCT NAME: QUIZARTINIB; REG. NO/DATE: EU/1/23/1768 20231107
1405852	CR 2015 00052	Denmark	⤷ Start Trial	PRODUCT NAME: EDOXABAN, OR A SALT THEREOF, A SOLVATE THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REG. NO/DATE: EU/1/15/993/001-028 20150623
1429780	13C0012	France	⤷ Start Trial	PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
0206283	SPC/GB97/085	United Kingdom	⤷ Start Trial	PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.